John Libbey Eurotext

Nouveaux médicaments antiépileptiques dans les épilepsies de l'enfant : intérêts et limites Volume 3, numéro spécial 3, Numéro spécial 2, December 2001

1. Perruca E, Gram L, et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998 ; 39 : 5-17.

2. Talwar D, Maninder S, et al. EEG changes and seizure exacerbation in young children treated with carbamazepine. Epilepsia 1994 ; 35 : 1154-9.

3. Buoni S, Grosso S, Fois A. Lamotrigine in typical absence epilepsy. Brain Dev 1999 ; 21 : 303-6.

4. Frank LM, Enlow T, Holmes G, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999 ; 40 : 973-9.

5. Motte J, Trevathan E, Arvidsson J, et al. Lamotrigine for generalised seizures associated with the Lennox-Gastaut syndrome. New Engl J Med 1997 ; 337 : 1807-12.

6. Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998 ; 39 : 508-12.

7. Kuenzle C, Steinlin M, Wohlrab G, et al. Adverse effects of vigabatrin in Angelman syndrome. Epilepsia 1998 ; 39 : 1213-5.

8. Appleton R, Peters ACB, et al. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999 ; 40 : 1627-33.

9. Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms : a randomized, prospective study. Epilepsia 1997 ; 38 : 1270-4.

10. Villeneuve N, Soufflet C, et al. Traitement des spasmes infantiles par vigabatrin en première intention et en monothérapie : à propos de 70 nourrissons. Arch Fr Péd 1998 ; 5 : 731-8.

11. Wohlrab G, Bolthauser E, et al. Vigabatrin as a first-line drug in West Syndrome : clinical and electroencephalographic outcome. Neuropediatrics 1998 ; 29 : 133-6.

12. Granström ML, Gaily E, et al. Treatment of infantile spasms: result of a population-based study with vigabatrin as the first drug for spasms. Epilepsia 1999 ; 40 : 950-7.

13. Chiron C, Dumas C, et al. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997 ; 26 : 389-95.

14. Villeneuve N, Dulac O. Vigabatrin in infantile spasms due to tuberous sclerosis (abstract). Epilepsia 1996 ; 37, (suppl 4) : 118.

15. Riikonen R. A long term follow-up study of 214 children with the syndrome of infantile spasms. Neuropediatrics 1982 ; 13 : 14-23.

16. Hrachovy RA, James D, et al. Double-blind study of ACTH versus prednisone therapy in infantile spasms. J Pediatrics 1983 ; 103 : 641-5.

17. Lombroso CT. A prospective study of infantile spasms : clinical and therapeutic correlations. Epilepsia 1983 ; 24 : 135-58.

18. Glaze DG, Hrachovy RA, et al. Prospective study of outcome of infants with infantile spasms treated during controlled studies of ACTH and prednisone. J Pediatrics 1988 ; 112 : 389-96.

19. Riikonen R, Donner M. ACTH therapy in infantile spasms : side effects. Arch Dis Child 1980 ; 55 : 664-72.

20. Schlumberger E, Dulac O. A simple, effective and well-tolerated treatment regime for West Syndrome. Dev Med Child Neurol 1994 ; 36 : 863-72.

21. Nabbout R, Chiron C, et al. Vigabatrin in partial seizures in children. J Child Neurol 1997 ; 12 : 172-7.

22. Lortie A, Chiron C, et al. Optimizing the indication of vigabatrin in children with refractory epilepsy. J Child Neurol 1997 ; 12 : 253-9.

23. Lawden MC, Eke T, et al. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999 ; 67 : 716-22.

24. Kalviainen R. Nousiainen I. Visual field defects with vigabatrin : epidemiology and therapeutic implications. CNS Drugs 2001 ; 15 : 217-30.

25. Hardus P, Verduin WM, et al. Visual field loss associated with vigabatrin : quantification and relation to dosage. Epilepsia 2001 ; 42 : 262-7.

26. Malmgren K, Ben-Menachem E, et al. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 2001 ; 42 : 609-15.

27. Paul SR, Krauss GL, et al. Visual function is stable in patient who continue long-term vigabatrin therapy : implication for clinical decision making. Epilepsia 2001 ; 42 : 525-30.

28. Prasad AN, Penney S, et al. The role of vigabatrin in childhood seizure disorders : results from a clinical audit. Epilepsia 2001 ; 42 : 54-61.

29. Iannetti P, Spalice A. Visual field constriction in children with epilepsy on vigabatrin treatment. Pediatrics 2000 ; 106 : 838-42.

30. Versino M, Veggiotti P. Reversibility of vigabatrin-induced visual-field defect. Lancet 1999 ; aug 7 ; 354 : 486.

31. Wohlrab G, Bolyhauser E, et al. Visual field constriction is not limited to children treated with vigabatrin. Neuropediatrics 1999 ; 30 : 130-2.

32. Harding GF, Wild JM, et al. Separating the retinal electrophysiologic effects of vigabatrin ; treatment versus field loss. Neurology 2000 ; 8 : 55 : 347-52.

33. Harding GF, Wild JM, et al. Electro-oculography, electroretinography, visual evoked potential, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction. Epilepsia 2000 ; 41 : 1420-31.

34. Miller NR, Johnson MA, et al. Visual dysfunction in patients receiving vigabatrin : clinical and electrophysiologic findings. Neurology 1999 ; 10 ; 53 : 2082-7.

35. Krauss GL, Johnson MA, et al. Vigabatrin-associated retinal cone system dysfunction. Electroretinogram and ophthalmologic findings. Neurology 1998 ; 50 : 614-8.

36. Arndt CF, Derambure P, et al. Outer retinal dysfunction in patients treated with vigabatrin. Neurology 1999 ; 52 : 1201-5.

37. Glauser TA, Miles MV, Tang P. Topiramate pharmacocinetics in infants. Epilepsia 1999 ; 40 : 788-91.

38. Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose ranging trial in refractory partial epilepsy using 600, 800, and 1 000 mg daily dosages. Neurology 1996 ; 46 : 1678-83.

39. Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the traitement of refractory partial epilepsy. Epilepsia 1996 ; 37 : 763-8.

40. Ben-Menachem E, Henriksen O, Mogens, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996 ; 37 : 539-43.

41. Sachdeo C, Reife A, et al. Topiramate monotherapy for partial onset seizures. Epilepsia 1997 ; 38 : 249-300.

42. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controled dose-ranging trial in refractory partial epilepsy using 200, 400, and 600 mg daily dosages. Neurology 1996 ; 46 : 1684-90.

43. Reife R, Pledger G, Lim P, et al. Topiramate pooled analysis of six placebo-controlled trials (Abstract). Epilepsia 1996 ; 37 (suppl 4) : 74.

44. Cramer JA, Fisher R, Ben-Menachem E, et al. New antiepileptic drugs : comparison of key clinical trials. Epilepsia 1999 ; 40 : 590-600.

45. Shorvon SD. Safety of Topiramate: adverse events and relation-ships to dosing. Epilepsia 1996 ; 37 (suppl 2) : S18-22.

46. Elterman RD, Glauser TA, Wyllie E, et al. A double-blind, randomised trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology 1999 ; 52 : 1338-44.

47. Glauser TA, Elterman R, Wyllie E. Long-term topiramate therapy in children with partial onset seizures. Neurology 1998 ; 50 : A99-100.

48. Sachdeo C, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 1999 ; 52 : 1882-7.

49. Bitton V, Montouris GD, Ritter F. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999 ; 52 : 1330-7.

50. Glauser TA, Clark P, Strawsburg ?. A Pilot study of topiramate in the treatment of infantile spasms. Epilepsia 1998 ; 39 : 1324-8.

51. Mikaeloff J, Rouselle C, Badinand N, et al. Expérience du topiramate dans une série de 40 enfants de moins de 12 ans. Communication à la 10e Réunion de la Société Française de Neurologie Pédiatrique, Toulouse, janvier 2000.

52. Matsuo F. Lamotrigine. Epilepsia 1999 ; 40 (suppl 5) : S30-36.

53. Eriksson AS, Hoppu K, et al. Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. Epilepsia 1996 ; 37 : 769-73.

54. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993 ; 43 : 2284-91.

55. Beran RG, Berkovic SF, Dunagan FM. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia 1998 ; 39 : 1329-33.

56. Schlumberger E, Chavez F, Palacios L, et al. Lamotrigine in tretment of 120 children with epilepsy. Epilepsia 1994 ; 35 : 359-67.

57. Eriksson AS, Nergardh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalised epilepsy : a randomized, double-blind, crossover study. Epilepsia 1998 ; 39 : 495-501.

58. Pisani F, Oteri G, et al. The efficacy of valproate-lamotrigine comedication in refractory complex partiel seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999 ; 40 : 1141-6.

59. Brodie MJ, Yuen AW. Lamotrigine substitution study : evidence for synergism with sodium valproate. Epilepsy Research 1997 ; 26 : 423-32.

60. Duchowny M, Pellock JM, Graf WD, et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal pediatric Partial Seizures Group. Neurology 1999 ; 53 : 1724-31.

61. Catania S, Cross H, de Sousa C, et al. Paradoxic reaction to lamotrigine in a child with benin focal epilepsy of childhood with centrotemporal spikes. Epilepsia 1999 ; 40 : 1657-60.

62. Kramer U, Ben-Zeev B, Harel S, Kivity S. Transient oromotor deficit in children with benign childhood epilepsy with central temporal spikes. Epilepsia 2001 ; 42 : 616-20.

63. Beran R, Gibson R. Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia 1998 ; 39 : 280-2.

64. Tecoma ES. Oxcarbazepine. Epilepsia 1999 ; 40 (suppl 5) : S37-46.

65. Dam M, Ekberg R, et al. A double-blind study comparing oxcarbazepine and carbazepine in patients with newly diagnosed, peviously untreated epilepsy. Epilepsy Res 1989 ; 3 : 70-6.

66. Nielsen OA, Johannessen AC, et al. Oxcarbazepine-induced hyponatremia, a cross-sectional study. Epilepsy Res 1988 ; 2 : 269-71.

67. Pendlebury SC, Moses DK, et al. Hyponatremia during oxcarbazepine therapy. Human Toxicol 1989 ; 8 : 337-44.

68. Reinikainen KJ, Kerânen T, Halonen T. Comparison of oxcarbazepine and carbamazepine : a double blind study. Epilepsy Res 1987 ; 1 : 284-9.

69. Gaily E, Granström Ml, Liukkonen E. Oxcarbazepine in the treatment in early childhood epilepsy. J Child Neurol 1997 ; 12 : 496-8.

70. Pellock JM, Watemberg N. New antiepileptic drugs in children : present and future. Semin Pediatr Neurol 1997 ; 4 : 9-18.

71. The Felbamate Study Group in Lennox-Gastaut Syndrome. New Engl J Med 1993 ; 328 : 29-33.

72. Dodson WE. Felbamate in the treatment of Lennox- Gastaut syndrome : result of 12-month, open-label study following a randomized clinical trial. Epilepsia 1993 ; 34 (suppl 7) : S18-24.

73. Pellock JM. Felbamate. Epilepsia 1999 ; 40 (suppl 5): S57-62.

74. UK Gabapentin Study Group. Gabapentin and partial epilepsy. Lancet 1990 ; 335 : 1114-7.

75. Baulac M, Cavalcanti D, Semah F, et al. Gabapentin add-on therapy with adaptable doses in 610 patients with partial epilepsy : an open observational study. The French Gabapentin Colaborative Group. Seizure 1998 ; 7 : 55-62.

76. Trudeau V, Myers S, et al. Gabapentin in naive childhood absence epilepsy : results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol 1996 ; 11 : 470-5.

77. Khaurana DS, Riviello J, et al. Efficacy of gabapentin therapy in children with refractory partal seizures. J Pediatr 1996 ; 128 : 829-33.

78. Appleton R, Fichtner K, La Moraux L. Gabapentin as add-on therapy in children with refractory partial seizures : a 12-week, multicentre, double-blind, placebo-controlled study. Epilepsia 1999 ; 40 : 1147-54.

79. Lee DO, Steingard RJ, et al. Behavioral side effects of gabapentin in children. Epilepsia 1996 ; 37 : 87-90.

80. Tallian KB, Nahata MC, et al. Gabapentin associated with aggressive behavior in pediatric patients with seizures. Epilepsia 1996 ; 37 : 501-2.

81. Wolf SM, Shinnar S, et al. Gabapentin toxicity in children manifesting as behaviour changes. Epilepsia 1996 ; 36 : 1203-5.

82. Schachter CS. Tiagabine. Epilepsia 1999 ; 40 (suppl 5) : S17-22.

83. Uthman BM, Rowan AJ, et al. Tiagabine for complex partial seizures : a randomized, add-on, dose response trial. Arch Neurol 1998 ; 55 : 56-62.

84. Sachdeo RC, Leroy RF, et al. Tiagabine therapy for complex partial seizures. Arch Neurol 1997 ; 54 : 595-601.

85. Kalvianainen R, Brodie MJ, et al. A double-blind, placebo controlled trial of tiagabine given three times daily as add-on therapy for refractory partial seizures. Northern European Tiagabine Study Group. Epilepsy Res 1998 ; 30 : 31-40.

86. Schachter SC, Deaton R, et al. Long-term use of tiagabine for partial seizures. Epilepsia 1997 ; 38 (suppl 8) : S105-6.

87. Uldall P, Bulteau C, et al. Single-blind study of safety, tolerability, and preliminary efficacy of tiagabine as adjunctive treatment of children with epilepsy. Epilepsia 1995 ; 36 (suppl 3) : S147-8.

88. Boellner S, Mc Carty, et al. Pilot study of tiagabine in children with partial seizures (abstract). Epilepsia 1996 ; 37 (suppl 4) : S92.

89. Perez J, Chiron C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia 40 : 1618-26.

90. Chiron C, Marchand PD, et al. Stiripentol in severe myoclonic epilepsy in infancy : a randomised placebo-controlled syndrome dedicated trial. Lancet 2000 ; 356 : 1638-42.